Apogee Therapeutics is a biotechnology startup that specializes in developing unique biological treatments for diseases with high unmet needs, such as atopic dermatitis (a type of skin inflammation), chronic obstructive pulmonary disease (a type of lung disease), and other inflammatory and immune diseases. The company aims to improve the current standard of care for these diseases, believing that patients deserve the best possible treatment.

Apogee's business model revolves around the creation and development of antibody therapeutics, which are drugs that can stimulate the body's immune system to fight diseases. These drugs target well-established biological drivers and development pathways, with a primary focus on improving treatments for atopic dermatitis and chronic obstructive pulmonary disease.

The company's revenue is likely generated through the sale of these therapeutics to healthcare providers and patients. It may also earn income from partnerships with other biotech firms or pharmaceutical companies, and potentially from grants or investments for research and development.

Apogee's team consists of experienced drug developers and operators who are motivated by the goal of providing better treatment options for people living with inflammatory and immune diseases. The company places a strong emphasis on creating a psychologically safe environment where everyone feels comfortable sharing ideas, reflecting its people-first philosophy.

Keywords: Biotechnology, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, Inflammatory Diseases, Immune Diseases, Antibody Therapeutics, Drug Development, Healthcare Providers, Patient Care, Psychological Safety.